The mission of the HIV Prevention Trials Network (HPTN) is to conduct research designed to identify the best combinations of HIV prevention interventions to prevent HIV infection in populations at the highest risk for this infection. The HPTN will be led by Drs. Wafaa EI-Sadr, Columbia University, and Myron S. Cohen, University of North Carolina at Chapel Hill, and supported by experienced operations, laboratory and statistical and data centers. The HPTN will address and support the two research Priority Areas in order to achieve the following eight Specific Aims:
Specific Aims for Priority Area 1: Integrate Strategies to Prevent HIV Infection:
Aim 1 : To develop an integrated strategy to prevent HIV infection in young women in Southern Africa;
Aim 2 : To develop integrated strategies to prevent HIV infection in men who have sex with men (MSM); Sub-aim 2a: To identify an integrated strategy to prevent HIV acquisition in HIV-uninfected MSM and transgender women in the Americas; Sub-aim 2b: To identify an integrated strategy to prevent HIV transmission from HIV-infected MSM in the United States (U.S.);
Aim 3 : To develop an integrated strategy to prevent HIV infection in injection drug users (IDUs) in Eastern Europe and Asia;
Aim 4 : To implement an integrated strategy to virtually eliminate (<1%) HIV transmission in discordant couples in sub-Saharan Africa {SSA};
Aim 5 : To develop methods to engage MSM in SSA in prevention research, paving the way for development of an integrated strategy to prevent HIV infection in this population Specific Aims for Priority Area 2: Pre-exposure Prophylaxis {PrEP}:
Aim 6 : To evaluate the efficacy of an ARV regimen containing maraviroc (MVC) for PrEP;
Aim 7 : To develop new agents for PrEP with favorable profiles, including long lasting agents;
Aim 8 : To develop pharmacostatistical models to define the role of new agents for PrEP.

Public Health Relevance

The research proposed by the HIV Prevention Trials Network (HPTN) aims to combine known interventions and identify new ones to stop the transmission of HIV infection with the goal of inspiring changes in public health policy and practice, and to ending the HIV epidemic.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI068619-14
Application #
9828044
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Gilbreath, Michael J
Project Start
2006-06-01
Project End
2020-11-30
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
14
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Family Health International
Department
Type
DUNS #
067180786
City
Durham
State
NC
Country
United States
Zip Code
27701
Lancaster, Kathryn E; Hoffman, Irving F; Hanscom, Brett et al. (2018) Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis. J Int AIDS Soc 21:e25195
Buchanan, Ashley L; Vermund, Sten H; Friedman, Samuel R et al. (2018) Assessing Individual and Disseminated Effects in Network-Randomized Studies. Am J Epidemiol 187:2449-2459
Ranganathan, Meghna; Heise, Lori; MacPhail, Catherine et al. (2018) 'It's because I like thingsā€¦ it's a status and he buys me airtime': exploring the role of transactional sex in young women's consumption patterns in rural South Africa (secondary findings from HPTN 068). Reprod Health 15:102
Grodensky, Catherine A; Golin, Carol E; Pack, Allison P et al. (2018) Adaptation and delivery of a motivational interviewing-based counseling program for persons acutely infected with HIV in Malawi: Implementation and lessons learned. Patient Educ Couns 101:1103-1109
Zhang, Yinfeng; Fogel, Jessica M; Guo, Xu et al. (2018) Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa. AIDS 32:1301-1306
Hill, Mandy J; Holt, Michael; Hanscom, Brett et al. (2018) Gender and race as correlates of high risk sex behaviors among injection drug users at risk for HIV enrolled in the HPTN 037 study. Drug Alcohol Depend 183:267-274
Eshleman, Susan H; Piwowar-Manning, Estelle; Sivay, Mariya V et al. (2018) Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. J Clin Virol 99-100:67-70
Tolley, Elizabeth E; Taylor, Jamilah; Pack, Allison et al. (2018) The Role of Financial Incentives Along the Antiretroviral Therapy Adherence Continuum: A Qualitative Sub-study of the HPTN 065 (TLC-Plus) Study. AIDS Behav 22:245-257
Bock, Peter; Jennings, Karen; Vermaak, Redwaan et al. (2018) Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa. J Acquir Immune Defic Syndr 77:93-101
Stoner, Marie C D; Edwards, Jessie K; Miller, William C et al. (2018) Does Partner Selection Mediate the Relationship Between School Attendance and HIV/Herpes Simplex Virus-2 Among Adolescent Girls and Young Women in South Africa: An Analysis of HIV Prevention Trials Network 068 Data. J Acquir Immune Defic Syndr 79:20-27

Showing the most recent 10 out of 192 publications